Search
Mainz Biomed NV
MYNZAdd to Watchlist
0.844USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
35.06MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-24.63%
Year to Date
-24.63%
1 Year
-40.56%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
1555.44%Turnover Ratio
0.844Prev. Close
0.000Low
0.00Turnover
LossP/E Static
0.05P/B
0.00%Div Yield TTM
--ROA
5.62052wk High
31.03Volume Ratio
-21.65MNet Profit
337.75KShares
-22.3610EPS TTM
0.30Beta
--ROE
0.54852wk Low
14.74%Amplitude
68.55%Gross Margin
35.06MMarket Cap
-1.34Reward/Risk
5.98%Risk Rate
TradingKey Stock Score of Mainz Biomed NV
Currency: USD Updated: 2026-03-11Key Insights
Mainz Biomed NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 59 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mainz Biomed NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Mainz Biomed NV Highlights
StrengthsRisks
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 68.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 893.99K.
Overvalued
The company’s latest PE is -0.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 529.62K shares, increasing 19.74% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
14.000
Target Price
+1650.00%
Upside Space
Mainz Biomed NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mainz Biomed NV Info
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Ticker SymbolMYNZ
CompanyMainz Biomed NV
CEOBaechler (Guido)
Websitehttps://www.mainzbiomed.com/
Related Instruments
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+5.81%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%Popular Instruments
52283.200
+28.900 (+0.06%)
29667.500
-131.800 (-0.44%)
7476.400
+0.900 (+0.01%)
14791.000
-564.000 (-3.67%)
68549.000
-936.000 (-1.35%)
6290.000
+14.600 (+0.23%)
68.024
+0.056 (+0.08%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4072.740
+41.970 (+1.04%)
FAQs
What is the current price of Mainz Biomed NV (MYNZ)?
The current price of Mainz Biomed NV (MYNZ) is 0.84.
What is the symbol of Mainz Biomed NV?
The ticker symbol of Mainz Biomed NV is MYNZ.
What is the 52-week high of Mainz Biomed NV?
The 52-week high of Mainz Biomed NV is 5.62.
What is the 52-week low of Mainz Biomed NV?
The 52-week low of Mainz Biomed NV is 0.55.
What is the market capitalization of Mainz Biomed NV?
The market capitalization of Mainz Biomed NV is 35.74M.
Is Mainz Biomed NV (MYNZ) currently rated as Buy, Hold, or Sell?
According to analysts, Mainz Biomed NV (MYNZ) has an overall rating of signal_hold, with a price target of 14.00.
What is the Earnings Per Share (EPS TTM) of Mainz Biomed NV (MYNZ)?
The Earnings Per Share (EPS TTM) of Mainz Biomed NV (MYNZ) is -2.70.